Search for Clinical Trial Results

Sponsored By

Neurofibromatosis Type 2 - 25 Studies Found

Status Study
Recruiting Study Name: Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Condition:
  • Vestibular Schwannoma
  • Neurofibromatosis Type 2

Date: 2016-10-13
Interventions: Drug: Icotinib Method of drug administration:oral; Dosage: 125mg/m3/d; Course of treatment: 3 months;Tot
Completed Study Name: Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Condition:
  • Vestibular Schwannoma
  • Neurofibromatosis Type 2

Date: 2014-03-26
Interventions: Drug: Endostatin Method of drug administration:continuous intravenous pumping; Dosage: 7.5mg/m2/d; Cours
Recruiting Study Name: Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Condition:
  • Neurofibromatosis Type 2
  • Vestibular Schwannomas

Date: 2014-04-29
Interventions: Drug: Axitinib Other Name: Inlyta
Completed Study Name: Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
Condition: Neurofibromatosis Type II
Date: 2011-08-17
Interventions: Drug: Everolimus (RAD001) , Afinitor® Everolimus will be provided by Novartis. Everolimus is formul
Suspended Study Name: PTC299 for Treatment of Neurofibromatosis Type 2
Condition: Neurofibromatosis 2
Date: 2009-05-28
Interventions: Drug: PTC299 PTC299 will be administered orally at 100 mg/dose twice per day for up to 1 year or until t
Recruiting Study Name: Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Condition:
  • Neurofibromatosis Type 2
  • Neuroma, Acoustic

Date: 2011-04-21
Interventions: Drug: RAD001, everolimus Adults: 10 mg p.o. daily dose, age 16 - 17: 3.0 mg/m2 p.o. daily
Completed Study Name: Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
Condition:
  • Acoustic Schwannoma
  • Neurofibromatosis Type 2

Date: 2010-09-01
Interventions:
  • Biological: bevacizumab Given

Active, not recruiting Study Name: Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
Condition:
  • Neurofibromatosis Type 2
  • Progressive Vestibular Schwannomas Date: 2013-01-07
    Interventions: Drug: Bevacizumab Treatment will be administered on an out
No longer available Study Name: Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients
Condition:
  • Neurofibromatosis Type 2
  • Severe Profound Sensorineural Hearing
    Date: 2015-10-27
    Interventions: Device: Nucleus Profile ABI541 Auditory Brainstem Implant
Completed Study Name: Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients
Condition: Neurofibromatosis 2
Date: 2011-11-30
Interventions: Drug: RAD001 10 mg per os / day or 05mg per os / day with 12 month
Next >>>